Skip to main content

Table 1 Clinical data of investigated patients, DPYD genotype and number of clones sequenced per patient.

From: Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy

      Toxicity grade   N clones
  Sex Age Tumor Regimen hematologic gastrointestinal dermatologic DPYD genotype (coding region/splice sites) Total Methylated
Patients with severe 5-FU related toxicity
1 m 53 Gastric 5FU-FA 1 3 0 - 21 0
2 f 70 Breast CAPE 0 3 0 c.85T>C, C29R; c.496A>G, M166V 20 0
3 f 55 Gastric CAPE-P 3 0 0 c.1601G>A, S534N 21 0
4 m 74 Colon 5FU-FA-P 4 4 0 - 20 0
5 f 53 Colon 5FU-FA-P 3 1 0 c.496A>G, M166V 21 0
6 m 66 Tonsil 5FU-P 2 3 3 c.85T>C, C29R; 1236G>A, E412E 20 0
7 m 53 Oesophagus 5FU-P 4 4 0 - 20 0
8 f 54 Breast E-5FU-C 3 1 0 1627A>G, I543V 21 0
9 f 65 Gastric E-5FU-P 3 1 2 - 22 0
10 m 79 Oesophagus 5FU-P 2 3 0 c.85T>C, C29R; c.1236G>A, E412E 20 0
11 f 67 Rectum 5FU-P 4 4 0 c.496A>G, M166V 22 0
12 f 57 Gastric E-5FU-P 3 1 0 c.85T>C, C29R; c.1236G>A, E412E; c.1627A>G, I543V 20 0
13 m 57 Rectum 5FU 3 0 0 1896T>C, F632F 21 0
14 m 67 unknowna 5FU-IRI 3 0 0 c.85T>C, C29R; c.1627A>G, I543V 24 0
15 f 50 Rectum 5FU-FA-P 1 3 0 c.85T>C, C29R 25 0
16 m 75 Gastric 5FU 2 3 0 - 21 0
17 f 47 Breast CAPE 1 1 3 c.85T>C, C29R; c.496A>G, M166V 30 0
Control patients
18 f 72 Rectum 5FU 1 1 0 - 20 0
19 f 54 Gastric 5FU-FA-P 2 1 0 c.1679T>G, I560S 21 0
20 m 59 Pancreas 5FU-FA-P 0 1 0 c.85T>C, C29R; c.1627A>G, I543V(H) 20 0
21 m 62 Colon 5FU-FA-P 0 1 0 c.85T>C, C29R (H); c.496A>G, M166V, c.1236G>A, E412E 19 0
22 f 64 Colon 5FU-FA 0 0 0 c.85T>C, C29R; c.1627A>G, I543V 20 0
23 m 63 Oesophagus 5FU-P 1 0 0 - 20 0
24 f 69 Colon 5FU-FA 0 1 0 c.85T>C, C29R (H); c.496A>G, M166V; c.2194G>A, V732I 20 0
25 m 59 Gastric 5FU-FA 1 1 0 c.85T>C, C29R; c.1627A>G, I543V; 1896T>C, F632F 21 0
26 m 59 Colon 5FU-FA-P 1 1 0 c.85T>C, C29R (H); c.496A>G, M166V; c.1627A>G, I543V 20 0
27 m 62 Gastric E-CAPE-P 2 1 2 c.85T>C, C29R (H); c.496A>G, M166V; c.1236G>A, E412E c.1627A>G, I543V 30 0
  1. Abbreviations: FA, folinic acid; CAPE, capecitabine; P, platinum compound; E, epirubicin; C, cyclophosphamide; H, homozygous carrier a adenocarcinoma of unknown origin